Gene therapy for type 1 diabetes: New approaches

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Type 1 or insulin-dependent diabetes mellitus is a metabolic disease that results from the destruction of pancreatic β-cells. Most patients receive subcutaneous insulin injections to reduce blood glucose levels. However, strict glucose control by multiple insulin injections is associated with an increased risk of hypoglycemia and weight gain, while a less strict glucose control is insufficient to prevent chronic complications such as nephropathy, neuropathy and retinopathy. Gene therapy holds a tremendous therapeutic potential to improve glycemic control by restoring endogenous insulin production. This review focuses on recent advances directed at producing insulin in an ectopic tissue as well as inducing pancreatic β-cell neogenesis. The strategies include constitutive and promoter-regulated insulin expression in the liver; increasing hepatic glucose oxidation; insulin production from intestinal cells; and islet cell neogenesis in liver and pancreas.

Original languageEnglish
Pages (from-to)93-104
Number of pages12
JournalMinerva Medica
Volume95
Issue number2
StatePublished - Apr 2004

Fingerprint

Type 1 Diabetes Mellitus
Genetic Therapy
Insulin
Glucose
Liver
Choristoma
Metabolic Diseases
Subcutaneous Injections
Islets of Langerhans
Hypoglycemia
Weight Gain
Blood Glucose
Pancreas
Injections

Keywords

  • Cell differentiation
  • Cell division
  • Diabetes mellitus, insulin dependent
  • Gene therapy
  • Promoter regions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gene therapy for type 1 diabetes : New approaches. / Morral, Nuria.

In: Minerva Medica, Vol. 95, No. 2, 04.2004, p. 93-104.

Research output: Contribution to journalArticle

@article{15ef5202460a47739c6f6ecd1894ba92,
title = "Gene therapy for type 1 diabetes: New approaches",
abstract = "Type 1 or insulin-dependent diabetes mellitus is a metabolic disease that results from the destruction of pancreatic β-cells. Most patients receive subcutaneous insulin injections to reduce blood glucose levels. However, strict glucose control by multiple insulin injections is associated with an increased risk of hypoglycemia and weight gain, while a less strict glucose control is insufficient to prevent chronic complications such as nephropathy, neuropathy and retinopathy. Gene therapy holds a tremendous therapeutic potential to improve glycemic control by restoring endogenous insulin production. This review focuses on recent advances directed at producing insulin in an ectopic tissue as well as inducing pancreatic β-cell neogenesis. The strategies include constitutive and promoter-regulated insulin expression in the liver; increasing hepatic glucose oxidation; insulin production from intestinal cells; and islet cell neogenesis in liver and pancreas.",
keywords = "Cell differentiation, Cell division, Diabetes mellitus, insulin dependent, Gene therapy, Promoter regions",
author = "Nuria Morral",
year = "2004",
month = "4",
language = "English",
volume = "95",
pages = "93--104",
journal = "Minerva Medicolegale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Gene therapy for type 1 diabetes

T2 - New approaches

AU - Morral, Nuria

PY - 2004/4

Y1 - 2004/4

N2 - Type 1 or insulin-dependent diabetes mellitus is a metabolic disease that results from the destruction of pancreatic β-cells. Most patients receive subcutaneous insulin injections to reduce blood glucose levels. However, strict glucose control by multiple insulin injections is associated with an increased risk of hypoglycemia and weight gain, while a less strict glucose control is insufficient to prevent chronic complications such as nephropathy, neuropathy and retinopathy. Gene therapy holds a tremendous therapeutic potential to improve glycemic control by restoring endogenous insulin production. This review focuses on recent advances directed at producing insulin in an ectopic tissue as well as inducing pancreatic β-cell neogenesis. The strategies include constitutive and promoter-regulated insulin expression in the liver; increasing hepatic glucose oxidation; insulin production from intestinal cells; and islet cell neogenesis in liver and pancreas.

AB - Type 1 or insulin-dependent diabetes mellitus is a metabolic disease that results from the destruction of pancreatic β-cells. Most patients receive subcutaneous insulin injections to reduce blood glucose levels. However, strict glucose control by multiple insulin injections is associated with an increased risk of hypoglycemia and weight gain, while a less strict glucose control is insufficient to prevent chronic complications such as nephropathy, neuropathy and retinopathy. Gene therapy holds a tremendous therapeutic potential to improve glycemic control by restoring endogenous insulin production. This review focuses on recent advances directed at producing insulin in an ectopic tissue as well as inducing pancreatic β-cell neogenesis. The strategies include constitutive and promoter-regulated insulin expression in the liver; increasing hepatic glucose oxidation; insulin production from intestinal cells; and islet cell neogenesis in liver and pancreas.

KW - Cell differentiation

KW - Cell division

KW - Diabetes mellitus, insulin dependent

KW - Gene therapy

KW - Promoter regions

UR - http://www.scopus.com/inward/record.url?scp=3042644926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042644926&partnerID=8YFLogxK

M3 - Article

C2 - 15272244

AN - SCOPUS:3042644926

VL - 95

SP - 93

EP - 104

JO - Minerva Medicolegale

JF - Minerva Medicolegale

SN - 0026-4806

IS - 2

ER -